{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:49:59Z","timestamp":1793713799482,"version":"4.6.1"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874312"],"award-info":[{"award-number":["81874312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104418"],"award-info":[{"award-number":["82104418"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1804197"],"award-info":[{"award-number":["U1804197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["18HASTIT047"],"award-info":[{"award-number":["18HASTIT047"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["202300410308"],"award-info":[{"award-number":["202300410308"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["212300410383"],"award-info":[{"award-number":["212300410383"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ201810"],"award-info":[{"award-number":["XYBSKYZZ201810"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.arr.2023.102021","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T02:08:10Z","timestamp":1690164490000},"page":"102021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The novel function of bexarotene for neurological diseases"],"prefix":"10.1016","volume":"90","author":[{"given":"Yangtao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.102021_bib1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.bbalip.2016.09.003","article-title":"The effect of regulating molecules on the structure of the PPAR-RXR complex","volume":"1861","author":"Amber-Vitos","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.arr.2023.102021_bib2","doi-asserted-by":"crossref","unstructured":"Anon 2022 Alzheimer's disease facts and figures. 2022. Alzheimers Dement, 18: 700\u201389.","DOI":"10.1002\/alz.12638"},{"key":"10.1016\/j.arr.2023.102021_bib3","doi-asserted-by":"crossref","unstructured":"Armstrong R, A Risk factors for Alzheimer's disease Folia Neuropathol. 57 2019 87 105.","DOI":"10.5114\/fn.2019.85929"},{"key":"10.1016\/j.arr.2023.102021_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12031-012-9866-6","article-title":"Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier","volume":"49","author":"Bachmeier","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JAD-150029","article-title":"The continuing failure of bexarotene in Alzheimer's disease mice","volume":"46","author":"Balducci","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102021_bib6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cmdc.201100156","article-title":"Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells","volume":"6","author":"Bauer","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.arr.2023.102021_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2021.108878","article-title":"Regulation of cholesterol biosynthesis and lipid metabolism: a microRNA management perspective","volume":"173","author":"Bhattarai","year":"2021","journal-title":"Steroids"},{"key":"10.1016\/j.arr.2023.102021_bib8","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2174\/1381612825666190801123235","article-title":"Inhibitory mechanism of an anticancer drug, bexarotene against amyloid beta peptide aggregation: repurposing via neuroinformatics approach","volume":"25","author":"Bibi","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.arr.2023.102021_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2007.12.2689","article-title":"Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-na\u00efve patients with advanced or metastatic non\u2013small-cell lung cancer: SPIRIT II","volume":"26","author":"Blumenschein","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.arr.2023.102021_bib10","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1523\/JNEUROSCI.5198-13.2014","article-title":"Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene","volume":"34","author":"Boehm-Cagan","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2014.03.029","article-title":"Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy","volume":"35","author":"Bomben","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2023.102021_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/endo.136.2.7835286","article-title":"Regulation of thyroid-stimulating hormone beta-subunit and growth hormone messenger ribonucleic acid levels in the rat: effect of vitamin A status","volume":"136","author":"Breen","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.arr.2023.102021_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.arr.2023.102021_bib14","first-page":"709","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021"},{"key":"10.1016\/j.arr.2023.102021_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102021_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.149044","article-title":"An ancestral nuclear receptor couple, PPAR-RXR, is exploited by organotins","volume":"797","author":"Capitao","year":"2021","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.arr.2023.102021_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mcna.2019.11.001","article-title":"Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management","volume":"104","author":"Capizzi","year":"2020","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.arr.2023.102021_bib18","doi-asserted-by":"crossref","first-page":"9173","DOI":"10.1523\/JNEUROSCI.1000-15.2015","article-title":"Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer's disease","volume":"35","author":"Casali","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12974-018-1091-y","article-title":"Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease","volume":"15","author":"Casali","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.arr.2023.102021_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.phrs.2015.10.009","article-title":"Activation of RXR\/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke","volume":"102","author":"Certo","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.arr.2023.102021_bib21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/STROKEAHA.119.027037","article-title":"Bexarotene enhances macrophage erythrophagocytosis and hematoma clearance in experimental intracerebral hemorrhage","volume":"51","author":"Chang","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2023.102021_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpb.2013.12.005","article-title":"Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation","volume":"87","author":"Chen","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.arr.2023.102021_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuron.2020.10.008","article-title":"Apolipoprotein E: structural Insights and Links to Alzheimer Disease Pathogenesis","volume":"109","author":"Chen","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2023.102021_bib24","unstructured":"Cheng, W. 2017. 'Electrophysiological Studies of The Antagonistic Effect of Bexarotene on A\u03b225\u201335 Induced Toxic Effects in Hippocampal CA1 Pyramidal Neurons', Tianjin Medical University."},{"key":"10.1016\/j.arr.2023.102021_bib25","unstructured":"Cheng, W., Y. Kou, Y. Zhang, J. Zhang, and L. Zhang. 2017. 'Antagonistic effect of bexarotene on A\u03b225\u201335-induced inhibiting action in glutamatergic synaptic transmission of hippocampal CA1 pyramidal neurons', Journal of Tianjin Medical University, Tianjin Medical University."},{"key":"10.1016\/j.arr.2023.102021_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.28455","article-title":"Molecular docking, dynamics, and pharmacology studies on bexarotene as an agonist of ligand-activated transcription factors, retinoid X receptors","author":"Chitranshi","year":"2019","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.arr.2023.102021_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1083\/jcb.138.3.671","article-title":"Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum\/intermediate compartment of NT2N cells","volume":"138","author":"Chyung","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.arr.2023.102021_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-1-4","article-title":"Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene","volume":"6","author":"Cohen","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.arr.2023.102021_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pnpbp.2017.11.016","article-title":"PSD95: a synaptic protein implicated in schizophrenia or autism?","volume":"82","author":"Coley","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.arr.2023.102021_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease","volume":"12","author":"Colom-Cadena","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.102021_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11481-015-9627-8","article-title":"ABCA1 is necessary for bexarotene-mediated clearance of soluble amyloid beta from the hippocampus of APP\/PS1 mice","volume":"11","author":"Corona","year":"2016","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.arr.2023.102021_bib32","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.102021_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/B978-0-444-64076-5.00046-6","article-title":"Multiple sclerosis","volume":"148","author":"Cotsapas","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tem.2016.03.018","article-title":"LXR regulation of brain cholesterol: from development to disease","volume":"27","author":"Courtney","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.arr.2023.102021_bib35","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib36","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1161\/STROKEAHA.113.002470","article-title":"N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARgamma agonist rosiglitazone","volume":"44","author":"Cuartero","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2023.102021_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.102021_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000358397","article-title":"Protective effects of bexarotene against amyloid-beta25-35-induced dysfunction in hippocampal neurons through the insulin signaling pathway","volume":"14","author":"Dai","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.arr.2023.102021_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.arr.2023.102021_bib40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s12975-020-00806-z","article-title":"Cell death pathways in ischemic stroke and targeted pharmacotherapy","volume":"11","author":"Datta","year":"2020","journal-title":"Transl. Stroke Res"},{"key":"10.1016\/j.arr.2023.102021_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00395-018-0699-5","article-title":"LXR\/RXR signaling and neutrophil phenotype following myocardial infarction classify sex differences in remodeling","volume":"113","author":"DeLeon-Pennell","year":"2018","journal-title":"Basic Res Cardiol."},{"key":"10.1016\/j.arr.2023.102021_bib42","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1007\/s12035-018-1041-9","article-title":"Bexarotene modulates retinoid-X-receptor expression and is protective against neurotoxic endoplasmic reticulum stress response and apoptotic pathway activation","volume":"55","author":"Dheer","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2023.102021_bib43","first-page":"9","article-title":"PPARdelta activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis","author":"Dickey","year":"2017","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.arr.2023.102021_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/1568026616666160617072521","article-title":"Natural and structure-based RXR ligand scaffolds and their functions","volume":"17","author":"Dominguez","year":"2017","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.arr.2023.102021_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5114\/fn.2020.100068","article-title":"Inhibition of MAPT enhances the effect of bexarotene and attenuates the damage after traumatic brain injury using in vivo and in vitro experiments","volume":"58","author":"Dong","year":"2020","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.arr.2023.102021_bib47","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.1121560109","article-title":"Extracting beta-amyloid from Alzheimer's disease","volume":"109","author":"Dries","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2023.102021_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13578-020-00393-4","article-title":"Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases","volume":"10","author":"Du","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.arr.2023.102021_bib49","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.arr.2023.102021_bib50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2003.05.068","article-title":"Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer","volume":"21","author":"Esteva","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.arr.2023.102021_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear receptors, RXR, and the big bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.arr.2023.102021_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1570159X15666170720095240","article-title":"Microglia and astrocytes in Alzheimer's disease: implications for therapy","volume":"16","author":"Fakhoury","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2023.102021_bib53","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.bbadis.2019.04.019","article-title":"Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells","volume":"1865","author":"Fanaee-Danesh","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.arr.2023.102021_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/cn400183w","article-title":"Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's beta-amyloid peptides","volume":"5","author":"Fantini","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1586\/14737140.4.2.180","article-title":"Bexarotene: a clinical review","volume":"4","author":"Farol","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.arr.2023.102021_bib56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport","volume":"36","author":"Fielding","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.arr.2023.102021_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000100355","article-title":"Amyloid-beta aggregation","volume":"4","author":"Finder","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.arr.2023.102021_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235809","article-title":"Comment on \"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\"","volume":"340","author":"Fitz","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.123025","article-title":"A highly sensitive and rapid LC-MS\/MS method for quantification of bexarotene in mouse plasma and brain tissue: application to mice pharmacokinetic study","volume":"1189","author":"Fu","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.arr.2023.102021_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712241","article-title":"The MS remyelinating drug bexarotene (an RXR Agonist) promotes induction of human tregs and Suppresses Th17 differentiation in vitro","volume":"12","author":"Gaunt","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.arr.2023.102021_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trci.2016.06.001","article-title":"A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects","volume":"2","author":"Ghosal","year":"2016","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2023.102021_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13024-015-0049-0","article-title":"Region-specific dendritic simplification induced by Abeta, mediated by tau via dysregulation of microtubule dynamics: a mechanistic distinct event from other neurodegenerative processes","volume":"10","author":"Golovyashkina","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2023.102021_bib63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnmt.118.218057","article-title":"Effects of Alzheimer disease on patients and their family","volume":"46","author":"Grabher","year":"2018","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.arr.2023.102021_bib64","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1021\/acschemneuro.1c00209","article-title":"OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP\/PS1 transgenic mice","volume":"12","author":"Guo","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1501244","article-title":"An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Abeta42 aggregates linked with Alzheimer's disease","volume":"2","author":"Habchi","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.arr.2023.102021_bib66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s11064-020-03216-7","article-title":"Ex vivo investigation of bexarotene and nicotinamide function as a protective agent on rat synaptosomes treated with abeta(1-42)","volume":"46","author":"Hacioglu","year":"2021","journal-title":"Neurochem Res"},{"key":"10.1016\/j.arr.2023.102021_bib67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2133.2003.05729.x","article-title":"Novel treatment of chronic severe hand dermatitis with bexarotene gel","volume":"150","author":"Hanifin","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.arr.2023.102021_bib68","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer's disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.arr.2023.102021_bib69","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.arr.2023.102021_bib70","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm0997-1016","article-title":"Distinct sites of intracellular production for Alzheimer's disease A beta40\/42 amyloid peptides","volume":"3","author":"Hartmann","year":"1997","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2023.102021_bib71","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nbd.2018.06.003","article-title":"Bexarotene protects against neurotoxicity partially through a PPARgamma-dependent mechanism in mice following traumatic brain injury","volume":"117","author":"He","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2023.102021_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113462","article-title":"Bexarotene promotes microglia\/macrophages - Specific brain - derived Neurotrophic factor expression and axon sprouting after traumatic brain injury","volume":"334","author":"He","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib73","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.arr.2023.102021_bib74","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","article-title":"Immune attack: the role of inflammation in Alzheimer disease","volume":"16","author":"Heppner","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib75","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0092-8674(92)90479-V","article-title":"9-cis retinoic acid is a high affinity ligand for the retinoid X receptor","volume":"68","author":"Heyman","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.arr.2023.102021_bib76","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.arr.2023.102021_bib77","doi-asserted-by":"crossref","first-page":"33176","DOI":"10.1038\/srep33176","article-title":"Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy","volume":"6","author":"Huuskonen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.102021_bib78","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/acschemneuro.7b00107","article-title":"Bexarotene does not clear amyloid beta plaques but delays fibril growth: molecular mechanisms","volume":"8","author":"Huy","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib79","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1134\/S0006297918090043","article-title":"Molecular pathogenesis in Huntington's disease","volume":"83","author":"Illarioshkin","year":"2018","journal-title":"Biochem. (Mosc. )"},{"key":"10.1016\/j.arr.2023.102021_bib80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2023.102021_bib81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fnins.2019.00735","article-title":"Targeting the synapse in Alzheimer's disease","volume":"13","author":"Jackson","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib82","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","article-title":"Seeding \u201cone-dimensional crystallization\u201d of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?","volume":"73","author":"Jarrett","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.arr.2023.102021_bib83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pneurobio.2017.10.001","article-title":"Blood-brain barrier dysfunction and recovery after ischemic stroke","volume":"163\u2013164","author":"Jiang","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.arr.2023.102021_bib84","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2174\/1568026620666200618114924","article-title":"Evidence linking protein misfolding to quality control in progressive neurodegenerative diseases","volume":"20","author":"Kabir","year":"2020","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.arr.2023.102021_bib85","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1021\/acschemneuro.8b00068","article-title":"Bexarotene binds to the amyloid precursor protein transmembrane domain, alters its alpha-helical conformation, and inhibits gamma-secretase nonselectively in liposomes","volume":"9","author":"Kamp","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and Abeta in Alzheimer's disease: accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2023.102021_bib87","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.2174\/1381612811319360006","article-title":"Schizophrenia: causes and treatments","volume":"19","author":"Khan","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.arr.2023.102021_bib88","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1871527317666180627120501","article-title":"Oxidative stress: major threat in traumatic brain injury","volume":"17","author":"Khatri","year":"2018","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.arr.2023.102021_bib89","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s00415-019-09541-4","article-title":"Recent advances in traumatic brain injury","volume":"266","author":"Khellaf","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib90","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1200\/JCO.2001.19.10.2626","article-title":"Multi-institutional phase I\/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer","volume":"19","author":"Khuri","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.arr.2023.102021_bib91","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan, Matthew","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.102021_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.05.007","article-title":"ATP-binding cassette transporter A1: from metabolism to neurodegeneration","author":"Koldamova","year":"2014","journal-title":"Neurobiol. Dis., 72 Pt A"},{"key":"10.1016\/j.arr.2023.102021_bib93","first-page":"8","article-title":"Oligodendrocytes in development, myelin generation and beyond","author":"Kuhn","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.arr.2023.102021_bib94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3233\/JAD-150469","article-title":"Bexarotene promotes cholesterol efflux and restricts apical-to-basolateral transport of amyloid-beta peptides in an in vitro model of the human blood-brain barrier","volume":"48","author":"Kuntz","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102021_bib95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrneurol.2017.69","article-title":"Modulators of microglial activation and polarization after intracerebral haemorrhage","volume":"13","author":"Lan","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/science.1234114","article-title":"Response to comments on \"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\"","volume":"340","author":"Landreth","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib98","first-page":"21","article-title":"ApoE lipidation as a therapeutic target in Alzheimer's disease","author":"Lanfranco","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102021_bib99","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fneur.2016.00100","article-title":"Opposite interplay between PPAR gamma and canonical Wnt\/Beta-catenin pathway in amyotrophic lateral sclerosis","volume":"7","author":"Lecarpentier","year":"2016","journal-title":"Front Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.nbd.2015.05.019","article-title":"RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment","volume":"82","author":"Lefterov","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2023.102021_bib101","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/mol.114.092163","article-title":"Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells","volume":"86","author":"Lehman","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.arr.2023.102021_bib102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31806450da","article-title":"Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial","volume":"31","author":"Lerner","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2023.102021_bib103","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.12m08160","article-title":"The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial","volume":"74","author":"Lerner","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.arr.2023.102021_bib104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2008.05.023","article-title":"PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle","volume":"202","author":"Lim","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arr.2023.102021_bib105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib106","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s11064-019-02902-5","article-title":"Bexarotene attenuates focal cerebral ischemia-reperfusion injury via the suppression of JNK\/Caspase-3 signaling pathway","volume":"44","author":"Liu","year":"2019","journal-title":"Neurochem Res"},{"key":"10.1016\/j.arr.2023.102021_bib107","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/endo.143.8.8930","article-title":"Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat","volume":"143","author":"Liu","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.arr.2023.102021_bib108","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jsps.2022.02.012","article-title":"iTRAQ-derived quantitative proteomics uncovers the neuroprotective property of bexarotene in a mice model of cerebral ischemia-reperfusion injury","volume":"30","author":"Liu","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.arr.2023.102021_bib109","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism","volume":"73","author":"Loboda","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.arr.2023.102021_bib110","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","article-title":"Glutathione synthesis","volume":"1830","author":"Lu","year":"2013","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.arr.2023.102021_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.182","article-title":"Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes","author":"Maekawa","year":"2017","journal-title":"Transl. Psychiatry, 7"},{"key":"10.1016\/j.arr.2023.102021_bib112","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acschemneuro.0c00707","article-title":"Evaluating novel RXR agonists that induce ApoE and tyrosine hydroxylase in cultured human glioblastoma cells","volume":"12","author":"Mallick","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib113","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/254560","article-title":"Identification of Bexarotene as a PPARgamma Antagonist with HDX","volume":"2015","author":"Marciano","year":"2015","journal-title":"PPAR Res"},{"key":"10.1016\/j.arr.2023.102021_bib114","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102021_bib115","doi-asserted-by":"crossref","first-page":"42270","DOI":"10.1038\/srep42270","article-title":"Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease","volume":"7","author":"Mariani","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.102021_bib116","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1007\/s12035-019-01665-y","article-title":"Autophagy induction by bexarotene promotes mitophagy in presenilin 1 familial Alzheimer's disease iPSC-derived neural stem cells","volume":"56","author":"Martin-Maestro","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2023.102021_bib117","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.arr.2023.102021_bib118","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/cn400100f","article-title":"Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease","volume":"4","author":"McFarland","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib119","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1997.15.2.790","article-title":"Initial clinical trial of a selective retinoid X receptor ligand, LGD1069","volume":"15","author":"Miller","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.arr.2023.102021_bib120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1567205013666161114115344","article-title":"Possible molecular interactions of bexarotene - a retinoid drug and Alzheimer's abeta peptide: a docking study","volume":"14","author":"Mirza","year":"2017","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2023.102021_bib121","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.4103\/1673-5374.274331","article-title":"Autophagy and inflammation in ischemic stroke","volume":"15","author":"Mo","year":"2020","journal-title":"Neural Regen. Res"},{"key":"10.1016\/j.arr.2023.102021_bib122","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103791","article-title":"The Alzheimer's disease-associated C99 fragment of APP regulates cellular cholesterol trafficking","volume":"39","author":"Montesinos","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.arr.2023.102021_bib123","doi-asserted-by":"crossref","first-page":"11862","DOI":"10.1523\/JNEUROSCI.1001-15.2015","article-title":"Bexarotene-activated retinoid X receptors regulate neuronal differentiation and dendritic complexity","volume":"35","author":"Mounier","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223578","article-title":"Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer s disease","volume":"14","author":"Munoz-Cabrera","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2023.102021_bib125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2310\/6620.2006.05051","article-title":"Cutaneous reactions to transdermal therapeutic systems","volume":"17","author":"Musel","year":"2006","journal-title":"Dermatitis"},{"key":"10.1016\/j.arr.2023.102021_bib126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s11064-015-1703-1","article-title":"New insights into epigenetic and pharmacological regulation of amyloid-degrading enzymes","volume":"41","author":"Nalivaeva","year":"2016","journal-title":"Neurochem Res."},{"key":"10.1016\/j.arr.2023.102021_bib127","doi-asserted-by":"crossref","first-page":"24048","DOI":"10.1038\/srep24048","article-title":"RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Abeta oligomers","volume":"6","author":"Nam","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2023.102021_bib128","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1093\/brain\/awv289","article-title":"Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination","volume":"138","author":"Natrajan","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.102021_bib129","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s12975-020-00867-0","article-title":"Aneurysmal subarachnoid hemorrhage: the last decade","volume":"12","author":"Neifert","year":"2021","journal-title":"Transl. Stroke Res"},{"key":"10.1016\/j.arr.2023.102021_bib130","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s13346-020-00816-2","article-title":"Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating","volume":"10","author":"de Oliveira Junior","year":"2020","journal-title":"Drug Deliv. Transl. Res"},{"key":"10.1016\/j.arr.2023.102021_bib131","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/mp200530q","article-title":"Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery","volume":"9","author":"Omtri","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.arr.2023.102021_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105208","article-title":"Aggregation and structure of amyloid beta-protein","volume":"151","author":"Ono","year":"2021","journal-title":"Neurochem Int"},{"key":"10.1016\/j.arr.2023.102021_bib133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.spen.2006.11.005","article-title":"Mechanisms of disease II: cellular protein quality control","volume":"14","author":"Outeiro","year":"2007","journal-title":"Semin Pedia Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib134","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","article-title":"Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease","volume":"72","author":"Ozben","year":"2019","journal-title":"Clin. Biochem"},{"key":"10.1016\/j.arr.2023.102021_bib135","article-title":"Bexarotene: a rare cause of misleading thyroid function tests","volume":"12","author":"Pattan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.arr.2023.102021_bib136","unstructured":"Pera, Marta, Jorge Montesinos, Delfina Larrea, Rishi R. Agrawal, Kevin R. Velasco, Irina G. Stavrovskaya, Taekyung D. Yun, and Estela Area-Gomez. 2020. 'MAM and C99, key players in the pathogenesis of Alzheimer\u2019s disease.' in, Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases."},{"key":"10.1016\/j.arr.2023.102021_bib137","doi-asserted-by":"crossref","first-page":"24329","DOI":"10.1039\/C8CP00049B","article-title":"Bexarotene cannot reduce amyloid beta plaques through inhibition of production of amyloid beta peptides: in silico and in vitro study","volume":"20","author":"Pham","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.arr.2023.102021_bib138","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JAD-150405","article-title":"Targretin improves cognitive and biological markers in a patient with Alzheimer's disease","volume":"49","author":"Pierrot","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102021_bib139","first-page":"58","article-title":"Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair","author":"Ploughman","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.arr.2023.102021_bib140","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCRESAHA.110.226860","article-title":"The PPAR-RXR transcriptional complex in the vasculature: energy in the balance","volume":"108","author":"Plutzky","year":"2011","journal-title":"Circ. Res"},{"key":"10.1016\/j.arr.2023.102021_bib141","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2174\/138955706778560120","article-title":"Silicon switches of marketed drugs","volume":"6","author":"Pooni","year":"2006","journal-title":"Mini Rev. Med Chem."},{"key":"10.1016\/j.arr.2023.102021_bib142","doi-asserted-by":"crossref","DOI":"10.1126\/science.1234089","article-title":"Comment on \"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\"","volume":"340","author":"Price","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib143","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/138920021702160114121706","article-title":"Preventive and therapeutic effects of the retinoid X receptor agonist bexarotene on tumors","volume":"17","author":"Qi","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.arr.2023.102021_bib144","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/psc.2789","article-title":"Abeta42 and Abeta40: similarities and differences","volume":"21","author":"Qiu","year":"2015","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.arr.2023.102021_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678744","article-title":"Immune cells in the BBB disruption after acute ischemic stroke: targets for immune therapy?","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.arr.2023.102021_bib146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-009-1140-4","article-title":"Bexarotene: a promising anticancer agent","volume":"65","author":"Qu","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.arr.2023.102021_bib147","first-page":"6","article-title":"Bexarotene upregulates mitochondrial autophagy and alleviates cerebral ischemia\/reperfusion injury in mice.","volume":"36","author":"Rao","year":"2020","journal-title":"Chin. Pharmacol. Bull."},{"key":"10.1016\/j.arr.2023.102021_bib148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","article-title":"Parkinson's disease: mechanisms, translational models and management strategies","volume":"226","author":"Raza","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.102021_bib149","first-page":"12","article-title":"A novel Co-crystal of bexarotene and ligustrazine improves pharmacokinetics and tissue distribution of bexarotene in SD rats","author":"Ren","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arr.2023.102021_bib150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fncel.2015.00250","article-title":"Neuroprotective effect of bexarotene in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis","volume":"9","author":"Riancho","year":"2015","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib151","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2015.11.058","article-title":"Retinoids and motor neuron disease: Potential role in amyotrophic lateral sclerosis","volume":"360","author":"Riancho","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2023.102021_bib152","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3816\/CLC.2001.n.005","article-title":"Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer","volume":"2","author":"Rizvi","year":"2001","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.arr.2023.102021_bib153","first-page":"1658","article-title":"A Phase I study of LGD1069 in adults with advanced cancer","volume":"5","author":"Rizvi","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.arr.2023.102021_bib154","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2133.1976.tb04379.x","article-title":"Contact dermatitis from antioxidants","volume":"94","author":"Roed-Petersen","year":"1976","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.arr.2023.102021_bib155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41467-020-20782-0","article-title":"Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single Abeta42 oligomers","volume":"12","author":"Ruggeri","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2023.102021_bib156","first-page":"10","article-title":"The clinical and neuropathological features of sporadic (late-onset) and genetic forms of Alzheimer's disease","author":"Rujeedawa","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.arr.2023.102021_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135764","article-title":"Retinoid X receptor activation promotes re-myelination in a very old triple transgenic mouse model of Alzheimer's disease","volume":"750","author":"Santos-Gil","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2023.102021_bib158","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4049\/jimmunol.1102942","article-title":"Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation","volume":"189","author":"Sanz","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.arr.2023.102021_bib159","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1523\/JNEUROSCI.4586-14.2015","article-title":"Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease","volume":"35","author":"Savage","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib160","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1570159X16666180412110919","article-title":"Inflammatory events following subarachnoid hemorrhage (SAH)","volume":"16","author":"Schneider","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2023.102021_bib161","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737140.2018.1449648","article-title":"Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers","volume":"18","author":"Shen","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.arr.2023.102021_bib162","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102021_bib163","first-page":"629","article-title":"The role of autophagy in the pathogenesis of ischemic stroke","volume":"19","author":"Shi","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2023.102021_bib164","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.arr.2023.102021_bib165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2002.08.001","article-title":"A phase II multicenter clinical trial of systemic bexarotene in psoriasis","volume":"51","author":"Smit","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.arr.2023.102021_bib166","unstructured":"Soria Lopez, J. A., H. M. Gonzalez, and G. C. Leger Alzheimer's disease Handb. Clin. Neurol. 167 2019 231 255."},{"key":"10.1016\/j.arr.2023.102021_bib167","doi-asserted-by":"crossref","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","article-title":"Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo","volume":"289","author":"Tai","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2023.102021_bib168","doi-asserted-by":"crossref","first-page":"29987","DOI":"10.1074\/jbc.M701700200","article-title":"p21WAF1\/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)\/retinoid X receptor (RXR) heterodimer and RXR\/RXR homodimer","volume":"282","author":"Tanaka","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2023.102021_bib169","unstructured":"'TARGRETIN (bexarotene) capsules, for oral use Initial U.S. Approval: 1999'. 2015. Food and Drug Administration, Accessed 2015\u201307-29. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021055s010lbl.pdf\u3009."},{"key":"10.1016\/j.arr.2023.102021_bib170","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233937","article-title":"Comment on \"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\"","volume":"340","author":"Tesseur","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib171","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/STROKEAHA.119.027315","article-title":"Brain cleanup as a potential target for poststroke recovery: the role of RXR (Retinoic X Receptor) in phagocytes","volume":"51","author":"Ting","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2023.102021_bib172","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-07-5185","article-title":"A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia","volume":"14","author":"Tsai","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.arr.2023.102021_bib173","first-page":"702","article-title":"Bexarotene attenuates early brain injury via inhibiting micoglia activation through PPARgamma after experimental subarachnoid hemorrhage","volume":"40","author":"Tu","year":"2018","journal-title":"Neurol. Res"},{"key":"10.1016\/j.arr.2023.102021_bib174","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-8-13","article-title":"In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis","volume":"8","author":"Ulrich","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2023.102021_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235505","article-title":"Comment on \"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\"","volume":"340","author":"Veeraraghavalu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.arr.2023.102021_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.613211","article-title":"Bexarotene impairs cognition and produces hypothyroidism in a mouse model of down syndrome and Alzheimer's disease","volume":"12","author":"Vidal","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.arr.2023.102021_bib177","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1523\/JNEUROSCI.1155-15.2015","article-title":"Nurr1 and retinoid X receptor ligands stimulate ret signaling in dopamine neurons and can alleviate alpha-synuclein disrupted gene expression","volume":"35","author":"Volakakis","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib178","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/MCB.16.7.3350","article-title":"Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor","volume":"16","author":"Vu-Dac","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.arr.2023.102021_bib179","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI1581","article-title":"Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids","volume":"102","author":"Vu-Dac","year":"1998","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.arr.2023.102021_bib180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.102021_bib181","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fnmol.2017.00294","article-title":"Modifications and trafficking of APP in the pathogenesis of Alzheimer's disease","volume":"10","author":"Wang","year":"2017","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2023.102021_bib182","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/jnen\/nlw049","article-title":"The effect of the APOE4 gene on accumulation of abeta40 after brain injury cannot be reversed by Increasing apoE4 protein","volume":"75","author":"Washington","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib183","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuropharm.2017.09.033","article-title":"Injury mechanisms in acute intracerebral hemorrhage","volume":"134","author":"Wilkinson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.102021_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104784","article-title":"APOE-amyloid interaction: therapeutic targets","volume":"138","author":"Wisniewski","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2023.102021_bib185","first-page":"20","article-title":"The Role of APOE and TREM2 in Alzheimer's disease-current understanding and perspectives","author":"Wolfe","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102021_bib186","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s12264-021-00735-3","article-title":"Pharmacological activation of RXR-alpha promotes hematoma absorption via a PPAR-gamma-dependent pathway after intracerebral hemorrhage","volume":"37","author":"Xu","year":"2021","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.arr.2023.102021_bib187","doi-asserted-by":"crossref","unstructured":"Xu, L. 2015. 'The protective effect and mechanism research of bexarotene on blood-brain barrier in cerebral ischemia-reperfusion injured rats', Chongqing medical university.","DOI":"10.1371\/journal.pone.0122744"},{"key":"10.1016\/j.arr.2023.102021_bib188","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-0038-1649502","article-title":"Multiple Sclerosis","volume":"38","author":"Yamout","year":"2018","journal-title":"Semin Neurol."},{"key":"10.1016\/j.arr.2023.102021_bib189","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1074\/jbc.275.7.4541","article-title":"Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT","volume":"275","author":"Yang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2023.102021_bib190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","article-title":"The pathogenicity of Th17 cells in autoimmune diseases","volume":"41","author":"Yasuda","year":"2019","journal-title":"Semin Immunopathol."},{"key":"10.1016\/j.arr.2023.102021_bib191","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbadis.2018.10.028","article-title":"OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing beta-amyloid clearance in APP\/PS1 mice","volume":"1865","author":"Yuan","year":"2019","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.arr.2023.102021_bib192","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jare.2021.06.023","article-title":"Activation of Nrf2\/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress","volume":"34","author":"Zhang","year":"2021","journal-title":"J. Adv. Res"},{"key":"10.1016\/j.arr.2023.102021_bib193","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of Alzheimer's disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102021_bib194","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/0963689719842161","article-title":"Bexarotene exerts protective effects through modulation of the cerebral vascular smooth muscle cell phenotypic transformation by regulating PPARgamma\/FLAP\/LTB4 after subarachnoid hemorrhage in rats","volume":"28","author":"Zhang","year":"2019","journal-title":"Cell Transpl."},{"key":"10.1016\/j.arr.2023.102021_bib195","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1074\/jbc.M113.526095","article-title":"Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor\/retinoic acid receptor pathway","volume":"289","author":"Zhao","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2023.102021_bib196","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2017.05.001","article-title":"The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice","volume":"65","author":"Zhong","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.arr.2023.102021_bib197","first-page":"3460","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonist troglitazone suppresses transforming growth factor-\u03b21 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro","volume":"8","author":"Zhu","year":"2016","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.arr.2023.102021_bib198","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12974-019-1432-5","article-title":"Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma\/SIRT6\/FoxO3a pathway after subarachnoid hemorrhage in rats","volume":"16","author":"Zuo","year":"2019","journal-title":"J. Neuroinflamm."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:13:28Z","timestamp":1761592408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723001800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":198,"alternative-id":["S1568163723001800"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.102021","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel function of bexarotene for neurological diseases","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.102021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102021"}}